Cite

HARVARD Citation

    Barkal, A. et al. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature immunology. pp. 76-84. [Online]. 
  
Back to record